Preliminary Safety Outcomes of Single Versus Dual Antiplatelet Therapy Combined with the Pipeline Flex Embolization Device with Shield Technology for Intracranial Aneurysm Treatment: A Retrospective Single-Center Analysis

In this exploratory study, no statistically significant difference was observed between the safety profiles of clopidogrel-based single and dual antiplatelet therapies for patients treated with the Pipeline Shield, despite the higher-risk baseline characteristics in the single-therapy cohort. These preliminary findings suggest that clopidogrel monotherapy might be a feasible alternative in select patients, potentially simplifying treatment and reducing DAPT-associated hemorrhagic complications.